Catalent's GPEx® Lightning Cell Line Development Technology

Published on: 

Sponsored Content

Shorten clinical development timeline using novel GPEx® Lightning technology

Speed and efficiency remain major drivers for developers advancing protein-based biologics to first-in-human studies. For 20 years, GPEx® technology has supported the generation of high expressing, highly stable mammalian cell lines with 16 commercially-approved biologics developed to date.

GPEx® Lightning further reduces development timelines and can be tailored to the specific needs of each individual program on its path to clinical trials.


Conference attending:

CPHI Frankfurt

Catalent will be exhibiting this year at CPHI Frankfurt 2022 on 1-3 November 2022. Come see us in person at booth #90G20.